EWTXEdgewise Therapeutics, Inc.
$39.02+174% 1Y
$39.02
$14.7052 weeks$46.97
EWTX as reported
- Net income
- −$197M
Net income · +31% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$159M
Free cash flow · +26% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.86
EPS · +20% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$197M | +31% | Q2 2026 |
| EPS | −$1.86 | +20% | Q2 2026 |
| ROE | −35% | n/a | Q2 2026 |
| ROA | −33% | n/a | Q2 2026 |
| Free cash flow | −$159M | +26% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Edgewise Therapeutics, Inc. (EWTX) · Net incomeNet incomeEdgewise Therapeutics, Inc. (EWTX)